Back

The role of ranolazine in managing chronic coronary syndrome: a synthesis of clinical outcomes and health economic modelling

28 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy and revascularisation: parallel ways to treat patients with chronic coronary syndromes Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Imad Alhaddad

Jordan Hospital, Amman (Jordan)

4 More presentations in this session

Presentation thumbnail
Dual versus single antiplatelet therapy after coronary artery bypass grafting: a meta-analysis of randomized controlled trials
Doctor T. Yoshida (New York, US)
Abstract Slides Video
Presentation thumbnail
Comparative efficacy of clopidogrel and aspirin monotherapy after dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Doctor N. Ktenopoulos (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Clopidogrel or prasugrel vs. aspirin monotherapy for long-term secondary prevention after percutaneous coronary intervention for acute coronary syndrome
Doctor Y. Iwanaga (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of antithrombotic strategies for atrial fibrillation in patients with chronic coronary syndrome according to coronary treatment strategy: a meta-analysis of randomized trials
Professor Y. Jeong (Gwangmyeong, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy and revascularisation: parallel ways to treat patients with chronic coronary syndromes

The Event

Event poster

ESC Congress 2026

28 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Session
Chronic coronary syndrome (CCS): the journey so far and the road to the future
31 August 2024
thumbnail
Congress Presentation
A value-based analysis of the systematic use of dapagliflozin in patients with heart failure
29 August 2025
thumbnail
Congress Presentation
Ranolazine therapy is associated with a reduced new diagnosis of diabetes mellitus in chronic coronary syndrome patients: the results of a real-world analysis of an Italian population
31 August 2024
thumbnail
Congress Presentation
An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a Danish healthcare perspective
7 April 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources